BioTuesdays

Category - Markets

Gemphire Logo
Markets

HCW starts Gemphire at buy

H.C. Wainwright launched coverage of Gemphire Therapeutics (NASDAQ:GEMP) with a “buy” rating and a price target of $21, saying it views the sell off in the shares following results of the ROYAL-1 clinical trial as...

August 31, 2017
KalVista Pharmaceuticals Logo
Markets

BTIG starts KalVista at buy

BTIG launched coverage of KalVista Pharmaceuticals (NASDAQ:KALV) with a “buy” rating and $18 price target. The stock closed at $6.59 on August 30. KalVista is focused on developing a portfolio of oral plasma kallikrein...

August 31, 2017
Innate Pharma Logo
Markets

HCW starts Innate Pharma at buy

H.C. Wainwright initiated coverage of French-based Innate Pharma (PSE:IPH) with a “buy” rating and price target of €16.50. The stock closed at €10.70 on August 29. Analyst Swayampakula Ramakanth writes that Innate is...

August 30, 2017
Intra Cellular Therapies
Markets

Ladenburg ups Intra-Cellular to buy

Ladenburg Thalmann upgraded Intra-Cellular Therapies (NASDAQ:ITCI) to “buy” from “neutral” with a $36 price target, reflecting a positive update from the FDA about the company’s schizophrenia program. The stock closed...

August 30, 2017
Clementia
Markets

Leerink starts Clementia at OP

Leerink launched coverage of Clementia Pharmaceuticals (NASDAQ:CMTA) with an “outperform” rating and $23 price target. The stock closed at $16.11 on August 25. Clementia’s lead asset, palovarotene, is a small molecule...

August 28, 2017
Foamix Pharmaceuticals
Markets

HCW starts Foamix at buy

H.C. Wainwright initiated coverage of Foamix Pharmaceuticals (NASDAQ:FOMX) with a “buy” rating and $12 price target. The stock closed at $4.53 on Aug. 23. Analyst Raghuram Selvaraju writes that Foamix is a rapidly...

August 24, 2017
PTC Therapeutics
Markets

WB starts PTC Therapeutics at MP

William Blair initiated coverage of PTC Therapeutics (NASDAQ:PTCT) with a “market perform” rating, citing a possibly tough road ahead for approval of the company’s ataluren in the U.S. The stock closed at $17.72 on Aug...

August 23, 2017
CymaBay
Markets

Leerink starts CymaBay at OP

Leerink initiated coverage of CymaBay Therapeutics (NASDAQ:CBAY) with an “outperform” rating and a price target of $12. The stock closed at $6.33 on Aug. 22. CymaBay is currently developing seladelpar for the lead...

August 23, 2017
Wave Life Sciences
Markets

Mizuho starts Wave Life Sciences at buy

Mizuho Securities initiated coverage of Wave Life Sciences (NASDAQ:WVE) with a “buy” rating and price target of $34. The stock closed at $17.50 on August 16. Analyst Salim Syed writes that Wave is an idea-rich, nucleic...

August 18, 2017